OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study

Ovarian cancer (OC) is one of the most lethal cancers in the world due to late-stage disease at diagnosis. Standard therapy consists of debulking surgery and chemotherapy. However, despite this aggressive treatment, recurrent disease almost invariably occurs resulting in a five-year survival rate of approximately 30%. Immunotherapy could be a way to increase survival in OC patients. However, a major barrier to a successful deployment of cancer immunotherapy for ovarian cancer patients is the immunosuppressive tumor microenvironment. Envisioned solution/research direction Tumor-related infla

Trial Details

NCT ID
NCT06611072
Phase
NA
Sponsor
Gynaecologisch Oncologisch Centrum Zuid
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Bone marrow aspiration
  • Vena puncture
  • Peritoneal fluid
  • Spleen biopsy
  • Tumor biopsy
  • Omental biopsy
Locations (sample)
  • Eindhoven, North Brabant, Netherlands|51.44083,5.47778

Key Eligibility Criteria

  • Subjects should be at least 18 years old and mentally competent;
  • Newly diagnosed patients with OC who go for primary debulking surgery or patients with OC who are scheduled for interval debulking;
  • Controls: women who undergo surgery for benign gynaecological conditions under general anaesthesia.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →